Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Bosutinib

2

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

2
Last update : 25/09/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Dasatinib
4
Imatinib
3
Nilotinib
2

Publications

Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Mar;29;511-516 2023 Mar
Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.
Clinical case reports 2021 May;9;e03164 2021 May
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
American journal of hematology 2014 Jul;89;732-42 2014 Jul
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Therapeutic advances in hematology 2014 Feb;5;13-7 2014 Feb
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood 2011 Oct 27;118;4567-76 2011 Oct 27

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies